HLB제약

047920KOSDAQ

53.2 / 100

Reference Date: 2026-09-08

Financial Score16.0 / 40

News Sentiment19.2 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 9.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Pharmaceuticals, established in 1998, focuses on specialty pharmaceutical manufacturing, CMO services, and health functional food sales. In 2025, it expanded into pharmaceutical distribution by acquiring 100% of Shinwha Advance, achieving a 2025 revenue of 2.055 trillion KRW with a 34% CAGR over five years. The company leverages its DDS technology for long-acting injectables and diversified growth through its joint health functional food brand 'Kwancheol'.

Number of Employees

185people

Average Salary

54.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

53.97Industry Average 15.000.0Point

3.6x industry avg (risky)

PBR

1.99Industry Average 1.201.0Point

1.7x industry avg (risky)

ROE

3.79Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

4.72Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲25.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲39.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -5.5% (improving, 3yr)

Detailed News Sentiment

8 totalPositive 6Neutral 2Negative 0Average Sentiment Score 76.9

Neutral
[비즈톡톡] 약가 인하 앞두고 로펌 찾는 제약사들, 왜
HLB제약 관련 제네릭 약가 인하 준비 과정에서 중소 제약사들이 로펌을 찾고 있으나, 직접적인 영향은 제한적임을 시사합니다.
Neutral
R&D 투자, '제네릭 약가' 좌우?준혁신형 도입에 셈법 달라진 제약사...
HLB제약의 R&D 투자 확대 필요성 언급으로 인해 직접적인 주가 영향은 제한적이나, 업계 동향에 대한 관심 증가로 소폭 상승 기대.
Positive
HLB이노베이션, HLB셀 지분 99.3% 인수…세포치료 역량 결집
HLB제약 관련 자회사 인수로 세포치료 분야 역량 강화 및 사업 확장 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 7,610Won52-week high 20,90052-week low 6,170

1-month return1.0Point

1m -9.30% (falling)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

13 totalPositive 0Neutral 13Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-09-03
Neutral효력발생안내( 2026.8.14. 제출 증권신고서(지분증권) )2026-09-01
Neutral[기재정정]투자설명서2026-09-01
Neutral주식등의대량보유상황보고서(일반)2026-08-31
Neutral[기재정정]증권신고서(지분증권)2026-08-31